Targeted Therapy in Hepatocellular Carcinoma
Author Information
Author(s): Chua Clarinda W. L., Choo Su Pin
Primary Institution: National Cancer Centre Singapore
Hypothesis
The article reviews important trials examining the use of targeted therapy in hepatocellular carcinoma (HCC) and explores future treatment strategies.
Conclusion
Targeted therapies, particularly sorafenib, have shown promise in improving survival for patients with advanced HCC, but further research is needed to optimize treatment strategies.
Supporting Evidence
- Sorafenib showed a median overall survival of 10.7 months compared to 7.9 months for placebo.
- 34% of patients achieved stable disease for at least 16 weeks with sorafenib.
- Patients with higher levels of pERK were more responsive to sorafenib treatment.
Takeaway
This study looks at new medicines that help treat liver cancer, showing that some can help people live longer, but more research is needed to find the best ways to use them.
Methodology
The article reviews various clinical trials and studies related to targeted therapies for HCC.
Potential Biases
Potential bias due to the selective inclusion of patients with better performance status and liver function.
Limitations
The studies reviewed often included patients with good liver function, limiting the applicability of results to those with poorer liver function.
Participant Demographics
The majority of participants were classified as Child-Pugh Class A, with a significant portion being hepatitis C positive.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI 0.55 to 0.87
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website